TIAN related Neurodamage Marker Screening Service

Online Inquiry

Background Service Highlights FAQs Contact Us

The Necessity of TIAN related Neurodamage Marker Screening

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of several refractory and relapsed hematological malignancies, and its application is rapidly expanding to solid tumors, including those of the central nervous system (CNS). However, this groundbreaking immunotherapy is associated with unique toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), cytokine release syndrome (CRS). A distinct neurotoxicity, tumor inflammation-associated neurotoxicity (TIAN), presents a significant challenge, particularly in CAR-T therapy for CNS tumors. Unlike the more systemic CRS or the broader ICANS, TIAN is characterized by localized inflammation within the tumor and the surrounding brain tissue. This localized inflammation can manifest in a variety of neurological symptoms, including headaches, fever, seizures, focal neurological deficits, and, in severe cases, fatal hydrocephalus. The unique pathophysiology of TIAN necessitates targeted diagnostic and monitoring strategies.

TIAN related Neurodamage Marker Screening Service at Creative Biolabs

Creative Biolabs offers a comprehensive TIAN related neurodamage marker screening service designed to address the critical need for improved diagnosis, risk stratification, and monitoring of this specific neurotoxicity. This service leverages cutting-edge technologies and Creative Biolabs' extensive expertise in biomarker discovery and validation to provide valuable insights into TIAN development and progression.

Unlocking the Biomarkers of TIAN

Creative Biolabs' TIAN related neurodamage marker screening service focuses on the identification and quantification of key biomarkers associated with TIAN and neuroinflammation within the CNS. These biomarkers may include, but are not limited to:

Pro-inflammatory cytokines: IL-6, TNF-α, IL-1β, and IFN-γ, which are implicated in the inflammatory cascade and blood-brain barrier disruption, key features of CAR-T related neurotoxicities.
Chemokines: CXCL10 and CCL2, which play a role in recruiting immune cells to the CNS and amplifying the inflammatory response.
Markers of blood-brain barrier (BBB) integrity: Proteins such as S100β and glial fibrillary acidic protein (GFAP), which can indicate BBB disruption.
Glial activation markers: Indicators of astrocyte and microglia activation, reflecting the neuroinflammatory process.

Advanced analytical techniques

The service employs a number of advanced analytical techniques, including:

Multiplex immunoassays: For simultaneous quantification of multiple biomarkers in a single sample.
High-sensitivity ELISA: For precise measurement of individual biomarker levels.
Flow cytometry: To analyze cellular markers associated with neuroinflammation.
Proteomics and genomics: For in-depth investigation of protein and gene expression profiles.

Highlights of Our Services

Creative Biolabs' TIAN related neurodamage marker screening service offers several key advantages:

Early Detection: Biomarkers can identify patients at risk of developing TIAN before the onset of severe clinical symptoms, enabling proactive intervention and potentially mitigating the severity of neurotoxicity.
Expert Consultation: Creative Biolabs provides expert consultation services to assist clients in interpreting biomarker data and translating findings into clinical practice.
Rigorous Validation: Creative Biolabs adheres to the highest standards of quality control and assay validation to ensure the accuracy, reliability, and reproducibility of biomarker measurements.

FAQs

Q1: What sample types are suitable for TIAN biomarker screening?

A1: Suitable sample types may include cerebrospinal fluid (CSF) and serum. CSF, due to its direct contact with the CNS, often provides the most relevant information on neuroinflammation. Serum, while more easily accessible, can also offer valuable data on systemic inflammatory responses that may contribute to TIAN. Creative Biolabs can provide guidance on optimal sample collection and processing procedures, including volume requirements, storage conditions, and the use of appropriate collection tubes to ensure sample integrity and minimize pre-analytical variability.

Q2: What the related services do you offer for the CAR-T therapy research and development?

A2: Creative Biolabs offers a wide range of related services to support CAR-T therapy research and development, including:
CAR T-cell characterization: Analysis of CAR expression, T-cell phenotype, and functional activity.
Cytokine profiling: Measurement of cytokine release in vitro and in vivo.
Preclinical model development: Assistance with establishing and validating animal models of CAR T-cell therapy and neurotoxicity.
Custom assay development: Development of novel assays to meet specific research needs.

Contact Us

Creative Biolabs is committed to advancing the field of CAR-T therapy and improving patient outcomes. Our TIAN related neurodamage marker screening service represents a significant step towards more effective and personalized management of CAR-T-associated neurotoxicity. Contact Creative Biolabs today to learn more about our services and how we can support your research and clinical development programs.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.